<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03471351</url>
  </required_header>
  <id_info>
    <org_study_id>RP6530+Pembrolizumab-1701</org_study_id>
    <nct_id>NCT03471351</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL</brief_title>
  <official_title>An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of RP6530, a Novel PI3K δ/γ Dual Inhibitor Given in Combination With an Anti-PD-1 Therapy, Pembrolizumab in Adult Patients With Relapsed or Refractory cHL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rhizen Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rhizen Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for
      Tenalisib in combination with Pembrolizumab in patients with cHL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL</measure>
    <time_frame>21 days</time_frame>
    <description>The MTD was defined as the highest dose level at which no more than 1 in 6 participants experienced a dose-limiting toxicity (DLT) during the first 21-day cycle of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>21 days</time_frame>
    <description>Assessment of Cmax in subjects treated with RP6530 and pembrolizumab combination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>No of patients with partial and complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>The time period from the response achieved in patient until the disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>Progression-free survival was defined as the time from enrollment in the study to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion Rate with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as improved outcome status (i.e Improve from PR to CR or from SD to PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving CR and PR with Tenalisib and Pembrolizumab combination</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tenalisib+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenalisib</intervention_name>
    <description>Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W</description>
    <arm_group_label>Tenalisib+Pembrolizumab</arm_group_label>
    <other_name>RP6530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W</description>
    <arm_group_label>Tenalisib+Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years on the day of signing informed consent.

          2. Histologically confirmed diagnosis of cHL.

          3. Disease status as defined as.

               -  Refractory patients who are naïve to anti-PD-1/PDL-1 therapy OR Relapsed after 3
                  or more lines of therapies; and are naïve to anti-PD-1/PDL-1 therapy OR

               -  Patients currently on Pembrolizumab and achieve a less than complete response

          4. Must have ECOG performance status of 0 or 1

          5. At least one bi-dimensional measurable lesion with minimum measurement of &gt; 15 mm in
             the longest diameter.

          6. Toxicities related to prior therapy must have returned to Grade 1 or less, except for
             alopecia.

               1. Adequate bone marrows, liver and renal function as assessed by the following
                  laboratory requirements. Hemoglobin ≥8.0 g/dL (may not be transfused or treated
                  with erythropoietin in preceding week to maintain or exceed this level)

               2. Absolute neutrophil count (ANC) ≥1,000/µL

               3. Platelet count ≥75,000/μL

               4. Total bilirubin ≤1.5 times the ULN (or ≤3 x ULN, if patient has Gilbert syndrome)

               5. ALT and AST ≤2.5 x ULN

               6. Serum creatinine ≤ 1.5 x ULN or CrCl &gt; 60 ml/min (Cockcroft-Gault formula)

          7. Use of an effective means of contraception for women of childbearing potential and men
             with partners of childbearing potential

          8. Provide written informed consent prior to any study-specific screening procedures.

          9. Willingness and capability to comply with the requirements of the study.

        Exclusion Criteria:

          1. Patient receiving anticancer therapy (e.g. chemotherapy, biologic therapy, hormonal
             therapy, surgery and/or tumor embolization) ≤3 weeks or 5 half-lives (whichever is
             shorter) prior to C1D1,

          2. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4
             antibody or any other antibody or drug specifically targeting T-cell co-stimulation or
             checkpoint pathways)

          3. Radiotherapy within the last 21 days prior to C1D1 (limited field palliative radiation
             is allowed if ≥ 14 days prior to C1D1);

          4. Investigational drug therapy outside of this trial during or within 3 weeks prior to
             C1D1.

          5. Patients with Allo-SCT on active GVHD or immunosuppression therapy within 3 months
             prior to C1D1.

          6. Patient with active autoimmune disease or any medical condition requiring the use of
             systemic immunosuppressive medications .

          7. Pregnancy or lactation.

          8. Known clinically active CNS involvement.

          9. Evidence of active Hepatitis B, active Hepatitis C infection (HCV) or cytomegalovirus
             (CMV) or known history of HIV.

         10. Subjects with concomitant second malignancies

         11. Patient with any active immune toxicity of Grade 1 or greater or any other severe or
             Grade 3 treatment-related adverse event.

         12. History of Grade 4 anaphylactic reaction to monoclonal antibody therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Radhakrishnan Ramchandren, MD</last_name>
    <phone>+001 313 576 8739</phone>
    <email>clinicaltrials@rhizen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rhizen Pharmaceuticals investigational trial site; Karmanos Cancer Institute,</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radhakrishnan Ramchandren, MD</last_name>
      <phone>313-576-8739</phone>
      <email>clinicaltrials@rhizen.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin lymphoma</keyword>
  <keyword>RP6530</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Tenalisib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

